- Welcome and introduction
- FDA-approved indications and pipeline
- Clinical and manufacturing process
- Toxicities and follow-up
- Audience question and answer
Date / Time
The goal of this activity is to improve the knowledge of hematology/oncology nurses, their ability to educate patients, and their competence in caring for patients with hematologic malignancies who have been prescribed CAR T-cell therapy or those that could benefit from CAR T-cell therapies
This program is intended for hematology/oncology nurses and other healthcare professionals who care for patients with hematologic malignancies that could benefit from CAR T-cell therapies.
Upon completion of this activity, participants should be able to:
- Describe the biologic principles underlying CAR T-cell therapy, structure, and function of the CAR, and the similarities and differences between currently available and emerging CAR T-cell therapies
- Integrate current data, indications, and guideline recommendations on CAR T-cell therapies for patients with leukemia, B-cell lymphomas, myeloma, or CLL/SLL into nursing practice
- Identify patients who may benefit from treatment or enrollment on a clinical trial investigating CAR T-cell therapy
- Manage toxicities associated with CAR T-cell therapy using available guidelines, online clinical resources, and tools
- Discuss with patients what to expect during CAR T-cell therapy process and the potential related complications following treatment
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.